RNA-seq to investigate impact of treatment of KRAS mutant A549 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib

Krupig, B., Hedley, A. and Murphy, D. (2018) RNA-seq to investigate impact of treatment of KRAS mutant A549 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib. [Data Collection]

Collection description

KRAS mutation is widely presumed to confer independence from upstream RTK signalling, however emerging evidence from mouse models of lung cancer suggests that ERBB RTKs may amplify signalling through RAS isoforms and participate in mutant RAS-driven lung cancer. This is one of 3 datasets where we examined the transcriptional impact of treatment of KRAS mutant human lung cancer cell lines with the multi-ERBB inhibitor Neratinib

College / School: College of Medical Veterinary and Life Sciences > Institute of Cancer Sciences
Date Deposited: 28 Mar 2019 12:12
URI: http://researchdata.gla.ac.uk/id/eprint/765

Available Files

There are no files in this dataset stored in the repository.

Please follow the links below to access data held elsewhere.

Repository Staff Only: Update this record

Krupig, B., Hedley, A. and Murphy, D. (2018); RNA-seq to investigate impact of treatment of KRAS mutant A549 lung adenocarcinoma cells with the multi-ERBB inhibitor Neratinib

ArrayExpress

http://researchdata.gla.ac.uk/765

Retrieved: 2020-10-30